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We present a case of a 67-year-old Japanese man with a serious oropharyngeal ulceration that at ﬁrst 
seemed to be destructive malignant lymphoma or oropharyngeal carcinoma.  We suspected methotrex-
ate (MTX)-associated lymphoproliferative disorder (LPD) induced by MTX treatment for rheumatoid 
arthritis (RA).  About 3 weeks after simple discontinuation of MTX,  complete regression of the dis-
ease was observed,  conﬁrming our diagnosis.
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ral ulceration can occur as a side eﬀect of 
methotrexate (MTX) therapy,  which may often 
be due to a lack of folic acid supplementation or an 
overdosage of the drug [1].  Adverse eﬀects,  which 
are experienced by up to 80ｵ of patients on long-
term,  low-dose MTX therapy,  may develop at any 
stage of treatment,  even after 30 years [2-4].  These 
eﬀects are usually mild and well tolerated,  and are 
relatively easily reversed by folate administration and 
either reduction or discontinuation of the drug [5].  
Iatrogenic lymphoproliferative disorders (LPD) are 
atypical lymphoid proliferations or lymphomas that 
arise in patients treated with immunosuppressive 
drugs such as MTX [6].  Although some case reports 
have described the spontaneous regression and disap-
pearance of lymphoproliferative lesions after simple 
discontinuation of MTX [7,  8],  MTX-associated 
LPDs in rheumatoid arthritis (RA) patients could be 
crucial and sometimes need aggressive treatment,  
including chemotherapy and/or radiation therapy [7,  
9].  Hence,  it is important to determine whether or not 
MTX-associated adverse events are reversible.  The 
present case report describes an RA patient with a 
seemingly critical oropharyngeal ulceration that was 
probably induced by MTX therapy and that indeed 
resolved immediately after MTX withdrawal.
Case Report
　 Clinical history. A 67-year-old Japanese man 
was referred to our department for evaluation of a 
large and deep ulceration over the right oropharynx,  
which limited his ability to open his mouth (Fig.  1).  
The ulceration looked as if a right tonsillectomy had 
been performed.  Although he had been experiencing 
pharyngeal pain for 6 months,  the pain had recently 
worsened enough to cause diﬃculty in ingestion and a 
tendency toward dehydration.  The rest of the physical 
examination of the head and neck region was unre-
markable.  There was no ulceration other than at the 
right oropharynx.  Full-body computed tomography 
revealed only the ulceration over the right orophar-
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ynx,  and no other abnormalities such as lymphade-
nopathy.
　 The patientʼs medical history revealed that he had 
suﬀered from RA for 23 years and was currently 
being treated with MTX,  prednisolone,  sodium auro-
thiomalate,  and diclofenac sodium.  He had been treated 
for over 20 years with a 6mg/week dose of MTX 
(oral administration) and 25mg/2 weeks of sodium 
aurothiomalate (intravenous injection),  and his disease 
had been controlled mainly by altering the dose of oral 
prednisolone (0-10mg/day).  The pain had been con-
trolled by diclofenac sodium (oral administration) with 
a maximum dose of 75mg/day.  There was no other 
medication than these 4 kinds of drugs.  Since his RA 
had progressively worsened,  the dosage of MTX had 
been gradually increased to a once-weekly dose of 
12mg/2 weeks during the 10 months prior to his cur-
rent history and presentation; administration of 
sodium aurothiomalate had been discontinued 10 
months earlier.  Our ﬁrst clinical impression was 
destructive malignant lymphoma or carcinoma of the 
oropharynx.  We also considered the possibility of 
MTX therapy as a causative even though we did not 
consider the dose of MTX to be very high.
　 To make a deﬁnitive diagnosis,  a biopsy of the 
ulcer was performed.  The biopsy samples demon-
strated an ulcer with granulation tissue,  and severe 
inﬂammatory cell inﬁltration was found in the submu-
cosa (Fig.  2A).  A high-power view revealed polymor-
phic features in the lesion,  namely,  numerous large 
atypical lymphoid cell proliferations with small lym-
phocytes (Fig.  2B).  On immunohistochemical study,  
the large atypical lymphoid cells were positive for 
CD20,  CD79a,  and CD30,  and negative for CD3 
(Fig.  2C).  These cells were also positive for Epstein-
Barr virus-encoded small RNA oligonucleotides (Fig.  
2D).  Thus,  a diagnosis of MTX-associated LPD was 
made.
　 In laboratory ﬁndings,  the white blood cell count 
was 8,310/µl; C-reactive protein,  5.64mg/dl (refer-
ence range, ＜0.30mg/dl); lactate dehydrogenase,  
215IU/l (120-240IU/l); and soluble interleukin-2 
receptor,  666U/ml (122-496U/ml).
　 The patient was admitted to our hospital to receive 
intravenous nourishment.  He was advised not to take 
any more MTX,  and was started on the intravenous 
administration of 10mg prednisolone/day.  Cessation 
of MTX gave him immediate relief from the pharyn-
geal pain.  Surprisingly,  a review after 3 weeks dem-
onstrated almost complete resolution of the ulcer and 
abatement of his symptoms (Fig.  3).  Our histological 
diagnosis of MTX-associated LPD was thus conﬁrmed 
by the clinical outcome.  The patient is now treated 
with prednisolone and tacrolimus hydrate,  and his RA 
remains well controlled.
Discussion
　 Since MTX mostly aﬀects cells undergoing rapid 
turnover,  including mucosal and bone marrow cells,  
myelosuppression and mucositis are among the more 
commonly reported adverse reactions to MTX [10].  
Oral ulceration is experienced by 14ｵ of patients on 
long-term,  low-dose MTX therapy,  and established 
lesions are exacerbated by further administration of 
the drug but heal within about 3 weeks after MTX 
discontinuation [11].  This side eﬀect of MTX is 
generally dose-dependent and often occurs due to an 
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Fig. 1　 A large and deep ulceration over the right oropharynx limited mouth opening.
accidental overdosage of MTX [12].  MTX is usually 
given in a once-weekly dose of up to 25mg [13].  
Hence,  it was not likely that the side eﬀect seen in our 
patient was due to overdosage of MTX,  because the 
maximum dosage in the present case was only 12mg/
week.  Oral side eﬀects are of signiﬁcance to the 
patient not only because of the pain but also as a fac-
tor aﬀecting diet,  exacerbating folate deﬁciency,  
causing weight loss,  and leading to a general deterio-
ration of health [14].  It has been reported that folic 
acid supplementation can result in a 79ｵ reduction in 
mucosal and gastrointestinal side eﬀects of MTX 
[15].  Aspirin and other nonsteroidal anti-inﬂamma-
tory drugs (NSAIDs) can reduce MTX excretion by 
their eﬀect on renal tubules.  Hence,  the British 
national formulary advises that the MTX dose should 
be carefully monitored in patients concurrently receiv-
ing aspirin or other NSAIDs [12].  When RA and oral 
ulceration worsen,  patients may be inclined to increase 
their NSAID dosage,  which might result in a vicious 
cycle that includes worsening of the oral ulceration.  
Our patient was also treated with diclofenac sodium,  
but the maximum dose was 75mg/day.  Although sodium 
aurothiomalate may also induce oral ulcers [16],  
administration of this drug in the present case was 
stopped at least 4 months prior before the symptom of 
pharyngeal pain ﬁrst occurred.
　 Adverse events with MTX are usually mild and well 
tolerated [5].  To our knowledge,  the ulceration of 
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Fig. 3　 Three weeks after the cessation of MTX,  almost com-
plete resolution of the ulcer was observed.  Now the patient can 
open his mouth fully.
Fig. 2　 The biopsy samples demonstrated an ulcer with granulation tissue,  and severe inﬂammatory cell inﬁltration was seen in the 
submucosa (A) (Hematoxylin and eosin staining).  A high-power view revealed polymorphic features of the lesion,  namely,  the proliferation 
of numerous large atypical lymphoid cells with small lymphocytes (B) (Hematoxylin and eosin staining).  On immunohistochemistry,  large 
atypical lymphoid cells were positive for CD20 (C),  CD79a,  and CD30,  and were negative for CD3.  Moreover,  large atypical lymphoid 
cells were positive for Epstein-Barr virus-encoded small RNA oligonucleotides (D).
the oropharynx in the present case seems to be the 
most advanced one associated with MTX therapy that 
has ever been reported.  Thus,  we considered that this 
ulceration was the LPD lesion itself,  not the advanced 
stage of oral ulceration or LPD combined with oral 
ulceration,  although it may be diﬃcult to show 
evidence to back up this assertion.  The frequency of 
extranodal occurrence of MTX-induced LPD is about 
40ｵ [17].  Since RA disease activity correlates with 
higher rates of malignant lymphoma and LPD [18],  
the possibility of iatrogenic LPD or malignant lym-
phoma was suspected in the present case.  In MTX-
associated LPD patients,  the mean duration of MTX 
treatment was 5.2 years (range,  1.4-13 years) with a 
mean cumulative dose of 2,200mg (range 500-5,200mg) 
[19].  In the present case,  the duration of treatment 
was about 20 years and the total dose of MTX was 
about 3,800mg.  Although it has been reported that 
there was no relationship between the total dose of 
MTX or the duration of MTX treatment and the 
occurrence of LPD in RA patients [17,  20,  21],  the 
extremely long period of MTX treatment in the pres-
ent case might be related to such a severe LPD lesion.  
In the present study,  histological examination and 
clinical outcome revealed a diagnosis of MTX-associated 
LPD,  which is a form of immunosuppression-related 
LPD.  As in the present case,  about 40ｵ of LPD in 
RA patients treated with MTX are EBV-positive [6,  
11].  Latent EBV infection may be involved in the 
development of EBV-associated B-cell LPDs,  like 
those occurring in immunosuppressed patients [21].  It 
is hypothesized that the withdrawal of MTX results in 
partial recovery of the immune system,  with subsequent 
elimination of the malignant clone due to enhanced 
oncogenic surveillance [22].  Although EBV-positive 
LPDs or lymphomas have a special tendency to undergo 
spontaneous remission after MTX is withdrawn [6,  
7],  it was striking that even such an extensive and 
destructive lesion,  as in the present case,  completely 
regressed within 3 weeks after MTX was simply 
withdrawn.  Steroidal or nonsteroidal anti-inﬂamma-
tory drug use is unlikely to have been responsible for 
the disease remission seen in our patient [23].  On the 
other hand,  EBV-associated lymphoma can sometimes 
be lethal [24].  Hence,  pathological examination was 
deemed to be important in the present case.  If no 
remission was seen within 3 weeks of MTX with-
drawal,  the therapeutic plan was to immediately treat 
the condition as a diﬀuse large B-cell lymphoma 
(DLBCL); most cases of these are non-Hodgkinʼs 
B-cell lymphomas of the large cell or diﬀuse mixed 
type [25],  although he did not perfectly fulﬁll the 
pathological criteria for DLBCL.
　 Physicians should be aware of the adverse eﬀects 
of MTX therapy and the possible value of MTX cessa-
tion with subsequent close monitoring for regression 
prior to considering radiotherapy or chemotherapy in 
patients receiving MTX therapy,  even if the lesions 
look like destructive lymphomas.  Further,  since some 
patients with initial regression of LPD after cessation 
of MTX experience a recurrence of LPD at a later 
date [26],  patients with MTX-associated LPD should 
continue to be monitored for a while,  even after com-
plete recovery from the disease.
　 In conclusion,  patients in whom MTX-associated 
lymphomas or LPDs are suspected should be initially 
managed by withdrawal of MTX.  If no regression is 
seen within 3 weeks after MTX cessation,  chemo-
therapy and/or radiation therapy should be considered 
as soon as possible in order to avoid disease progres-
sion.  Histological diagnosis and close monitoring for 
regression after MTX cessation are important in these 
patients.
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